Global Health - Highest-Standard Care; High Complexity Work; Axis Securities Initiates Coverage With A Buy

Axis Securities Report

We initiate coverage on Global Health Ltd. with a Buy recommendation and DCF-based target price of Rs 1,475/share (enterprise value/Ebitda of 26.5 times FY27E Ebitda), implying an upside of 25% from the current marktet price. Medanta boasts a robust Brand Equity, established by Dr. Trehan, a globally recognized cardiovascular and cardiothoracic surgeon.

The company has fortified its position with a strong moat, providing the highest standard of care and specializing in high-complexity work. A diverse revenue mix, notably from complex specialties like Cardiac, Digestive, Oncology, and Neuro (constituting 59% of overall revenue), contributes significantly to its financial profile.

Additionally, the Institute of Liver Transplantation, Kidney and Urology, Orthopedics, and Internal Medicine involve intricate procedures, further propelling the company's topline growth.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.